Working... Menu

Dose Finding Study of BI 836880 in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02674152
Recruitment Status : Active, not recruiting
First Posted : February 4, 2016
Last Update Posted : February 15, 2019
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
This is a Phase I, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously. The eligible patient population will be patients with advanced solid tumours. At any time during the trial, it will not be permitted to escalate to a dose which does not fulfil the escalation with overdose control (EWOC) criterion

Condition or disease Intervention/treatment Phase
Neoplasms Drug: BI 836880 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors.
Actual Study Start Date : January 5, 2016
Actual Primary Completion Date : September 12, 2018
Estimated Study Completion Date : May 16, 2019

Arm Intervention/treatment
Experimental: BI 836880 Drug: BI 836880

Primary Outcome Measures :
  1. The primary endpoint to assess the maximum tolerated dose (MTD) is based on the number of patients presenting dose-limiting toxicities (DLTs) using CTCAE v4.03, judged to be related to the study medication evaluated over the first cycle of treatment. [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Number of patients experiencing drug related AE leading to dose reduction or discontinuation from start of treatment until end of treatment [ Time Frame: up to 24 weeks ]
  2. Exposure measures (AUC0-tz) after the first dose [ Time Frame: 36 weeks ]
  3. Disposition kinetic measures (t1/2 ) after the first dose [ Time Frame: 36 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Age >= 18 years
  • Histologically or cytologically confirmed malignancy which is locally advanced or metastatic solid tumor, and either refractory after standard therapy for the disease or for which standard therapy is not reliably effective, e.g. they do not tolerate or have contraindications to otherwise available standard therapy and tumour lesions evaluable for Dynamic contrast-enhanced (DCE)-MRI at MTD.
  • ECOG performance status <= 2
  • Adequate hepatic, renal and bone marrow functions
  • Signed written informed consent.
  • Life expectancy min. 3 months in the opinion of the investigator
  • Recovery from all reversible adverse events of previous anti-cancer therapies to baseline or CTCAE grade 1, except for alopecia (any grade) sensory peripheral neuropathy CTCAE grade <= 2 or considered not clinically significant.
  • adequate contraception by male and female patient during the trial and for at least 6 months after end of treatment.

Exclusion criteria:

  • Known hypersensitivity to the trial drugs or their excipients
  • Current or prior treatment with any systemic anti-cancer therapy either within 28 days or a minimum of 5 half-lives, whichever is shorter of trial onset.
  • Serious concomitant disease, especially those affecting compliance with trial requirements or which are considered relevant for the evaluation of the endpoints of the trial drug
  • Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment, or planned surgical procedures during the trial period.
  • patients with personal or family history of QT prolongation and/or long QT syndrome, or prolonged QTcF at baseline (> 470 ms). QTcF will be calculated by Investigator as the mean of the 3 ECGs taken at screening.
  • Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure > NYHA II). Uncontrolled hypertension defined as: blood pressure in rested and relaxed condition >=140 mmHg systolic, or >=90 mmHg diastolic (with or without medication), measured according to protocol.
  • History of severe haemorrhagic or thromboembolic event in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).
  • Known inherited predisposition to bleeding or to thrombosis in the opinion of the investigator.
  • Patient with brain metastases that are symptomatic and/or require therapy.
  • Patients who require full-dose anticoagulation (according to local guidelines).
  • Active alcohol or drug abuse in the opinion of the investigator.
  • Patients who are under judicial protection and patients who are legally institutionalized.
  • Patients unable or unwilling to comply with protocol
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02674152

Layout table for location information
INS Curie
Paris, France, 75248
Kommunalunternehmen Klinikum Augsburg
Augsburg, Germany, 86156
Universitätsklinikum Freiburg
Freiburg, Germany, 79106
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02674152     History of Changes
Other Study ID Numbers: 1336.1
2014-005395-28 ( EudraCT Number )
First Posted: February 4, 2016    Key Record Dates
Last Update Posted: February 15, 2019
Last Verified: February 2019